Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits
The company acquired Everyday Health in December.
If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.
Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role
Mylan reports third-quarter loss; analysts say drug-pricing restrictions less likely under Trump; the FDA limits citizen petitions
FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast
Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences
Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health
England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development
Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin
Red, a Huntsworth agency, also counted Sanofi as a new client.
Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations
The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
The company said growth in its immunology portfolio offset declining Olysio sales.
The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.
Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.
The drugmaker recently launched a DTC campaign for diabetes drug Trulicity, which generated $73.7 million in sales in the third quarter.
The Danish drugmaker said it expects an FDA decision about long-acting—and long-delayed—insulin Tresiba in October.
The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.
Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.
First-quarter results show prescription weight-loss drugs continue to struggle with market and mind share.
The company partnered with AstraZeneca and BioMarin to identify which patients respond to experimental cancer drugs.
Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company
Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.
Sales of the new cancer drug topped expectations since its February launch.
First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.
- Deloitte taps Havas Lynx's Mickelberg as MD
- Five things for pharma marketers to know: Wednesday, February 22, 2017
- Five things for pharma marketers to know: Thursday, February 23, 2017
- Five things for pharma marketers to know: Tuesday, February 21, 2017
- How VAYA Pharma used Facebook ads for its ADHD campaign